Logotype for Idorsia Ltd

Idorsia (IDIA) investor relations material

Idorsia Status Update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Idorsia Ltd
Status Update summary8 Sep, 2025

Innovation and Mechanism of Action

  • TRYVIO (aprocitentan) is the first FDA-approved dual endothelin receptor antagonist for systemic hypertension, offering a novel mechanism for patients with difficult-to-control hypertension after decades of limited progress.

  • It targets both ETA and ETB receptors, providing efficacy in upregulated endothelin systems and a strong safety and tolerability profile.

  • The endothelin pathway is particularly relevant for high-risk groups, including Black patients, elderly, postmenopausal women, obese individuals, and those with CKD, diabetes, heart failure, or sleep apnea.

  • TRYVIO is included in updated ACC/AHA guidelines and is nominated for the 2025 Prix Galien USA Awards.

Clinical Evidence and Patient Populations

  • Clinical trials demonstrated rapid, significant, and sustained blood pressure reductions, including in high-risk and resistant hypertension subgroups, with effects seen as early as two weeks and maintained up to 48 weeks.

  • TRYVIO showed unique efficacy in reducing nighttime blood pressure and urine albumin-to-creatinine ratio, with stable eGFR in CKD stage 3/4 patients.

  • Blood pressure-lowering effects were consistent across age, sex, race, BMI, kidney function, and diabetes status.

  • The FDA-approved label covers a broader population than the trial, including adults inadequately controlled on other antihypertensives and highlights cardiovascular risk reduction.

  • TRYVIO demonstrated good tolerability, minimal side effects, no drug-drug interactions, and no signals for hyperkalemia or hypotension, supporting its use in patients on multiple therapies.

Market Opportunity and Commercial Strategy

  • Nearly 26 million US patients are inadequately controlled on other drugs and eligible for TRYVIO, with 30–50% of treated patients falling into this category.

  • An initial focus is on 7 million easily identifiable patients, especially those with CKD, who have limited options and for whom TRYVIO is approved down to EGFR 15.

  • Over 1,000 physician interactions confirm strong recognition of TRYVIO's efficacy, safety, and unique mechanism, with favorable payer responses and a WACC set at $775/month.

  • Geographic expansion opportunities exist in the EU, UK, Japan, China, and further value is possible through IP extension, fixed-dose combinations, and new indications.

  • TRYVIO is approved and commercially available in the US since October 2024, also approved as JERAYGO in the EU and UK, with applications under review in Canada and Switzerland.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Idorsia earnings date

Logotype for Idorsia Ltd
Q3 202530 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Idorsia earnings date

Logotype for Idorsia Ltd
Q3 202530 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Idorsia Ltd is a biopharmaceutical company based in Switzerland, specializing in the discovery, development, and commercialization of small molecules. The company targets a wide range of diseases, including Fabry disease, insomnia, resistant hypertension, cerebral vasospasm, epilepsy, nasal polyposis, and systemic lupus erythematosus, among others. Idorsia's approach spans multiple therapeutic areas such as CNS, cardiovascular, and immunological disorders, as well as orphan diseases. The company is headquartered in Allschwil, near Basel, Switzerland, and its shares are listed on the SIX Swiss Exchange.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage